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Abstract
Background: Overproduction of proinflammatory cytokines from activated microglia has been implicated as an
important contributor to pathophysiology progression in both acute and chronic neurodegenerative diseases.
Therefore, it is critical to elucidate intracellular signaling pathways that are significant contributors to cytokine
overproduction in microglia exposed to specific stressors, especially pathways amenable to drug interventions. The
serine/threonine protein kinase p38a MAPK is a key enzyme in the parallel and convergent intracellular signaling
pathways involved in stressor-induced production of IL-1b and TNFa in peripheral tissues, and is a drug
development target for peripheral inflammatory diseases. However, much less is known about the quantitative
importance of microglial p38a MAPK in stressor-induced cytokine overproduction, or the potential of microglial
p38a MAPK to be a druggable target for CNS disorders. Therefore, we examined the contribution of microglial
p38aMAPK to cytokine up-regulation, with a focus on the potential to suppress the cytokine increase by inhibition
of the kinase with pharmacological or genetic approaches.
Methods: The microglial cytokine response to TLR ligands 2/3/4/7/8/9 or to Ab1-42 was tested in the presence of a
CNS-penetrant p38a MAPK inhibitor, MW01-2-069A-SRM. Primary microglia from mice genetically deficient in p38a
MAPK were used to further establish a linkage between microglia p38a MAPK and cytokine overproduction. The in
vivo significance was determined by p38a MAPK inhibitor treatment in a LPS-induced model of acute
neuroinflammation.
Results: Increased IL-1b and TNFa production by the BV-2 microglial cell line and by primary microglia cultures
was inhibited in a concentration-dependent manner by the p38a MAPK-targeted inhibitor. Cellular target
engagement was demonstrated by the accompanying decrease in the phosphorylation state of two p38a MAPK
protein substrates, MK2 and MSK1. Consistent with the pharmacological findings, microglia from p38a-deficient
mice showed a diminished cytokine response to LPS. Further, oral administration of the inhibitor blocked the
increase of IL-1b in the cerebral cortex of mice stressed by intraperitoneal injection of LPS.
Conclusion: The p38a MAPK pathway is an important contributor to the increased microglial production of
proinflammatory cytokines induced by diverse stressors. The results also indicate the feasibility of targeting p38a
MAPK to modulate CNS proinflammatory cytokine overproduction.
Keywords: Microglia, cytokines, toll-like receptors, knockout mice, p38alpha mitogen-activated protein kinase, amyloid beta-peptides, drug discovery
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Background
Microglia, the resident macrophages of the central nervous system (CNS), monitor their environment through
a constant movement of their processes, and respond to
local stressors and immune disturbances [1,2]. Microglia
express a complement of pattern recognition receptors
(PRR) that can respond to pattern associated molecular
patterns (PAMPs) and damage associated molecular patterns (DAMPs), such as Lipopolysaccharides (LPS) and
b-amyloid (Ab). A major class of PRRs includes the
Toll-like receptors (TLRs) that play a pivotal role in
host defense by regulating innate immunity and linking
with adaptive immune responses (for reviews, see: [3,4]).
Activation of TLRs on microglia leads to the production
of inflammatory mediators, such as IL-1b, IL-6, TNFa,
and nitric oxide. TLR engagement and signaling in the
CNS provide an important defense mechanism by which
microglia respond to external pathogens or host-derived
ligands. Microglia can also be activated by inflammatory
mediators (e.g. cytokines and chemokines) from autocrine, paracrine, and endocrine sources (for detailed
reviews on microglia, see: [5,6]). The local environment,
and possibly intrinsic changes to the microglia determine how the cells will respond to the activating signals
[7,8]. Like peripheral immune cells, microglia can adopt
a number of activated phenotypes, and the functional
outcome depends on a complex balance between beneficial protective responses and detrimental harmful
responses [9]. Tight regulation of microglial activation
pathways is essential for appropriate responses to stressor stimuli and maintenance of CNS homeostasis,
because uncontrolled or dysregulated inflammatory
responses can lead to propagation of detrimental and
neurotoxic responses.
A relevant example is the control of microglia proinflammatory cytokine production in response to various
ligands. Proinflammatory cytokines have many important
physiological functions in the CNS, from protection
against pathogens to acting as neuromodulators affecting
cognition [10]. However, clinical studies and preclinical
animal models have implicated dysregulation and overproduction of proinflammatory cytokines from activated
microglia in the CNS as a contributor to pathophysiology
progression in both chronic neurodegenerative disorders
such as Alzheimer’s disease (AD), Parkinson’s disease,
and multiple sclerosis, as well as acute neurodegenerative
conditions such as traumatic brain injury and stroke
[11-13]. Taken in its entirety, the evidence is consistent
with the hypothesis that proinflammatory cytokine overproduction is a comparatively early event in the progression of pathophysiology that is causally linked to synaptic
dysfunction, behavior deficits and, in the more extreme
case, neuronal death. This raises the possibility that

Page 2 of 12

up-regulation of proinflammatory cytokine production
could be targeted in new therapeutic development strategies with potential for disease modification in multiple
diseases and clinical presentations.
One approach to targeting CNS cytokine dysregulation
is to modulate the intracellular signal transduction cascades that regulate the production of proinflammatory
cytokines. This requires that we explore which specific signal transduction pathways are involved in cytokine overproduction in microglia exposed to different stressors, and
which of these pathways are amenable to intervention. A
major signaling pathway that contributes quantitatively to
up-regulated cytokine production in peripheral inflammation is the p38 mitogen activated protein kinase (MAPK)
pathway, especially the key regulatory enzyme p38a
MAPK [14,15]. The p38a MAPK is amenable to therapeutic intervention in peripheral inflammatory diseases, and
treatment with p38a MAPK-targeted inhibitors can suppress cytokine levels back towards basal. There is increasing evidence that the p38 MAPK signaling cascade also
contributes to CNS cytokine overproduction and neurodegenerative sequelae, and that it may be a good therapeutic
target for CNS disorders characterized by increased proinflammatory cytokine production as a contributor to neurologic dysfunction or susceptibility to injury [11,16].
However, studies are needed to determine a direct linkage
between the p38a MAPK-mediated pathway in microglia
and proinflammatory cytokine production in response to
different stressors. In addition, whether the pathway in
microglia is druggable; i.e., responsive to intervention with
CNS-penetrant kinase inhibitors, needs to be determined.
The field has been limited in its ability to pursue these
questions because of the lack of selective p38a MAPK
inhibitors with sufficient brain penetrance and metabolic
stability for use in CNS disorders [17]. We recently
developed a selective, orally bioavailable, CNS-penetrant,
small molecule p38a inhibitor, MW01-2-069A-SRM
(069A) [18]. Compound 069A attenuates hippocampal
proinflammatory cytokine overproduction and leads to
improved neurologic outcomes in an AD-relevant
mouse model when administered orally at a low dose
and in a clinically relevant time window of disease progression; specifically, 069A suppressed the Ab 1-42 induced hippocampal IL-1b and TNFa up-regulation
back towards basal and attenuated the resultant synaptic
dysfunction and behavioral deficits [18]. These data provided an initial causative link between p38a MAPK and
CNS disease-related endpoints. Moreover, pharmacological downregulation of IL-1b production may have
important protective consequences, as IL-1b can induce
the expression and activation of p38 MAPK in neurons,
promoting tau phosphorylation and loss of the synaptic
protein synaptophysin [19,20]. The availability of this
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p38a MAPK inhibitor, as well as a novel mouse model
where p38a MAPK is genetically deleted in microglia,
provide the opportunity to test whether p38a MAPK
is a major regulator of microglial proinflammatory
cytokine overproduction in response to specific stressors, and whether this signaling pathway is amenable
to intervention. We report here that p38a MAPK is a
key contributor to microglia proinflammatory cytokine
production in response to a variety of stressor stimuli,
including Ab 1-42 and different TLR ligands. In addition, inhibition of p38a MAPK by either pharmacological or genetic approaches leads to a reduction in
microglia cytokine production. The results indicate the
feasibility of targeting p38a MAPK in attempts to
modulate proinflammatory cytokine overproduction, a
potential contributor to CNS disease progression and
susceptibility.
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Small molecule p38a MAPK inhibitor synthesis and
compound administration

The p38a MAPK inhibitor, 3-phenyl-4-(pyridin-4-yl)-6(4-pyrimidin-2-yl)piperazin-1-yl)pyridazine (MW01-2069A-SRM) (hereafter designated 069A) was synthesized
according to the production scheme previously
described [18]. Stock solutions of 069A were made in
sterile 0.9% sodium chloride that was free of preservatives (Hospira, Inc., Lake Forest, IL: cat. no. NDC 04094888-10). Solutions for cell treatments were prepared by
dilution of the stock solutions into serum-free media
immediately before adding to the cells. Compound was
added to cell cultures just before addition of the stressor
stimulus, except for the experiment in Figure 1C, D that
tested different times of compound addition. For in vivo
experiments, mice received 069A (5 mg/kg) or the saline

100%

100%

75%

75%

Oligomeric Ab1-42 was prepared from recombinant Ab142 peptide (rPeptide, Athens, GA: cat. no. A-1002-2) as
previously described [21,22]. Briefly, the Ab peptide was
monomerized in 1mM hexafluoroisopropanal (HFIP)
(Sigma-Aldrich, St. Louis, MO), and the HFIP was evaporated using a SpeedVac. The dried peptide film was
stored in a desiccator at -20°C until use. Oligomeric Ab
was prepared by resuspending the peptide in 5 mM
dimethylsulfoxide (DMSO) (Sigma-Aldrich, St. Louis,
MO; cat. no. D2650). The peptide was then diluted to
100 μM in phenol red-free F12 media (Promocell, Heidelberg, Germany; cat. no. C-72119). The Ab solution
was incubated for 24 hrs on ice at 4°C to allow oligomer
formation. Oligomeric Ab was used at a final concentration of 5 μM for stimulation of rat microglia cultures.
Vehicle control used the same volumes of DMSO and
F12 media as was used to generate the Ab peptide preparations and followed all steps as the peptide.
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Lipopolysaccharides (LPS) from Salmonella enterica serotype typhimurium (Sigma-Aldrich, St. Louis, MO: Cat.
no. L6143-1MG; EU/MG of LPS is 600,000) was prepared in sterile 0.9% sodium chloride. The following
TLR ligands were prepared according to the manufacturer instructions (InvivoGen, San Diego, CA): the TLR2
ligand, lipoteichoic acid (LTA) from Staphylococcus aureus (10 μg/ml), (cat. no. tlrl-pslta); TLR-3 ligand, polyinosine-polycytidylic acid (poly(I:C)) low molecular
weight (1mg/ml)(0.2-1kb; cat. no. tlrl-picw) and a high
molecular weight (50 μg/ml) (1.5-8kb; cat. no. tlrl-pic);
TLR7/8 ligand, CL097, (500ng/ml)(cat. no. tlrl-c97); and
TLR 9 ligand, type B CpG oligonucleotide, ODN1668
(500ng/ml)(cat. no. tlrl-modnb).
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Figure 1 The small molecule p38a MAPK inhibitor, 069A,
suppresses the LPS-induced increase in cytokine production by
the BV-2 microglia cell line. BV-2 cells were stimulated with
100ng/ml of LPS in the absence or presence of increasing
concentrations of 069A (0.9 - 30 μM). 069A inhibited LPS-induced IL1b (A) and TNFa (B) production in a concentration-dependent
manner, with an IC50 of 3.7 μM and 4.5 μM, respectively. Compound
069A (4 μM) was equally as effective in blocking the IL-1b (C) and
TNFa (D) cytokine response to LPS when the compound was given
at the same time as LPS (time 0) or when given at different times
after LPS exposure. White bars show the response of the LPS
stimulated cells in the absence of 069A. Gray bars show the
response to LPS in the presence of 069A. Data are expressed as a
percent of the maximal activity, where activity in the presence of
LPS alone is taken as 100%. Asterisk denotes significance (*** = p <
0.001) in response to LPS in the absence (white bars) or presence
(gray bars) of 069A.
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vehicle by oral gavage (po) in a volume of 200 μL one hr
prior to the LPS injection.
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littermates (used as wild-type controls). Genotyping was
performed by Transnetyx, Inc (Cordova, TN) to confirm
mouse genotypes.

Cel Culture

Mixed glial cultures were prepared from the cerebral
cortex of 1-2 day old neonatal C57Bl/6 mice or Sprague-Dawley rats as previously described [23]. The cells
were maintained for 2-6 weeks in a-minimum essential
medium (a-MEM) supplemented with 10% fetal bovine
serum (FBS) (US Characterized FBS; Hyclone; Cat no.
SH3007103N), 100 IU/ml penicillin, 100 μg/ml streptomycin (Mediatech Cat no. 30-002-CI) and 2mM L-Glutamine (Mediatech Cat no. 25-005-CI). Microglia were
isolated from the mixed glial cultures by the shake-off
procedure [24]. Briefly, the flasks were shaken for 2 hr
at 250 rpm on an orbital shaker at 37°C, the media containing loosely adherent cells were harvested into 48well plates at 1 × 105 or in a 12-well plate at 3 × 105.
After 30 min, nonadherent cells were removed and fresh
serum-free medium supplemented with 5ng/ml M-CSF
(R&D systems; Cat no. 416-ML) was added. The cells
were then cultured for 24 hrs before treatment.
The murine microglial BV-2 cell line [25] was cultured
in DMEM/F12 (Mediatech; Cat no. #15-090-CV) supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml
streptomycin (Mediatech Cat no. 30-002-CI) and 2mM
L-Glutamine (Mediatech Cat no. 25-005-CI). For experiments, serum-containing medium was removed and
cells were treated with stimulus or vehicle control in
serum-free medium. Cells were harvested after 1 hr of
stimulation for Western blot analysis, and after 18 hrs
of stimulation for cytokine measurements.
Animals

All experiments were conducted in accordance with the
principles of animal care and experimentation in the
Guide For the Care and Use of Laboratory Animals.
The Institutional Animal Care and Use Committees of
the University of Kentucky and Northwestern University
approved the use of animals in this study. Neonatal
C57Bl/6 mice or Sprague-Dawley rats were used to
make primary glial cultures. Male and female, 2-monthold, C57Bl/6 mice (Harlan) were used for the in vivo
LPS experiment. The p38a conditional knockout mice
were generated as previously described [26]. Briefly, the
first exon of the p38a gene was flanked by two loxP
sites, the floxed allele was bred to homozygosity, and
then crossed with mice that contain Cre driven by the
lysozyme promoter. The mice (all p38a fl/fl and backcrossed to C57Bl/6) are maintained and bred as follows:
Female mice that are p38fl/fl wildtype and not carrying
the Cre allele are bred with male mice that are Lys-Cre
hemizygotes. This generates litters where ~50% mice are
microglia p38a knockout and ~50% are p38a fl/fl

Western blotting

BV-2 cells or primary microglia were plated in 12 well
plates at a density of 1 × 105 cells/well or 3 × 105 cells/
well, respectively. Western blotting analysis was performed as previously described [27]. Cell lysates were
prepared in sodium dodecyl sulfate (SDS)-containing
sample buffer and equal volumes of cell lysates were
separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). After transfer to Immobilon-P membranes (Millipore) and blocking, blots were probed with
the following primary antibodies from Cell Signaling
Technology (Beverly, MA): rabbit anti-pMSK1 (cat. no.
9595 (1:1000)); rabbit anti-pMK2 (cat. no. 3041
(1:1000)); rabbit anti-pCREB (cat. no. 9191 (1:1000));
and rabbit anti-pATF2 (cat no. 9221 (1:1000)): mouse
anti-pp38a/b (cat no. 9216 (1:1000)); rabbit anti-p38a/b
(cat no. 9212 (1:1000)); rabbit anti-p38a (cat no. 9218
(1:1000)); mouse anti-b-Actin (Cat no. 3700 (1:10000)).
In vitro cytokine measurements

After testing a number of different cell densities, a BV-2
cell density of 2 × 104 in a 48 well plate incubated for 24
hrs prior to addition of stimulus produced the most consistent cytokine response with the lowest intra- and interassay variability (data not shown). Primary microglia were
used in 48-well plates at 1 × 105 cells. Levels of TNFa
were measured in the conditioned media by ELISA using
kits from Meso Scale Discovery (MSD; Gaithersburg,
Maryland)(Figure 1&2) or R&D Systems (Minneapolis,
MN) (Figure 3&4). For IL-1b, cell lysates were prepared in
lysis buffer containing 20mM Tris, pH8; 2mM EDTA;
0.5% Triton X-100. Levels of IL-1b were measured in the
conditioned media by ELISA using kits from MSD (Figure
1&2) or R&D Systems (Figure 3&4).
Tissue collection and cytokine measurements

At 90 min and 6 hrs after LPS administration, mice
were injected with an overdose of sodium pentobarbital
(Pentasol powder; Vibrac Animal Health, Ft Worth, TX:
cat. no. NDC-051311-103-25). Blood was collected for
serum cytokine measurements. The mice were then
decapitated. The brain was dissected on ice and snapfrozen in liquid nitrogen. The tissue was stored at -80°C
until time of use. Brain cortex was homogenized using
high shear homogenizer (Omni TH115), in a 1:10 (w/v)
of ice-cold freshly prepared lysis buffer consisting of
PBS containing 1 μg/ml Leupeptin, 1mM PMSF, and
1mM EDTA. The cortical homogenate was centrifuged
at 14,000xg for 20 minutes at 4°C in a microcentrifuge.
Fifty microliters of the resulting supernatant was loaded

Bachstetter et al. Journal of Neuroinflammation 2011, 8:79
http://www.jneuroinflammation.com/content/8/1/79

A: p-MK2

Page 5 of 12

A: IL-1β

B: p-MSK1

B: TNFα

60
125%

TLR9

TLR4

TLR7/8

TLR3

0

TLR2

TNFα (pg/ml)

2000

Media

D: p-ATF2

4000

TLR9

0

TLR4

- + + + + + + +
- -

20

TLR7/8

069A

40

TLR3

0%
LPS

- + + + + + + +
- -

125%

125%

C: IL-1β

75%

***
50%

p-ATF2 (%)

100%

*

125%
75%

25%

25%

0%
LPS

0%
LPS

- + + + + + + +
- -

TLR2

069A

TLR4

TLR7/8

TLR9

100%

50%

- + + + + + + +
- -

Figure 2 The p38a inhibitor, 069A, selectively inhibits
phosphorylation of the p38a substrates MK2 and MSK1 in LPSstimulated BV-2 microglia cells. BV-2 cells were stimulated with
100ng/ml of LPS in the absence or presence of increasing
concentrations of 069A (0.9 - 30 μM). Levels of (A) p-MK2 and (B) pMSK1 were suppressed by the p38a inhibitor in a concentrationdependent manner. Treatment of cells with 069A had an effect on
p-CREB (C) only at the two highest compound concentrations, and
had no effect on p-ATF2 levels (D). Gray bars show the response of
control, unstimulated cells; white bars show the response of LPSstimulated cells in the absence of 069A; black bars show the
response of LPS-stimulated cells in the presence of 069A. For each
endpoint, data are expressed as a percent of the maximal activity,
where activity in the presence of LPS alone is taken as 100%.
Asterisk denotes significance (* = p < 0.05, ** = p < 0.01, or *** = p
< 0.001) in endpoint for LPS-stimulated cells (white bars) to LPSstimulated cells in presence of 069A (black bars). Data represent five
independent experiments.
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Figure 3 The p38a MAPK inhibitor 069A attenuates the IL-1b
and TNFa increase in response to diverse TLR ligands. The IL1b (A) and TNFa (B) response from BV-2 cells was measured after
18 hrs of stimulation with either: (TLR2) 10 μg/ml LTA; (TLR3) 50 μg/
ml poly(I:C); (TLR4) 100ng/ml LPS; (TLR7/8) 500ng/ml CL097; or
(TLR9) 500ng/ml ODN1668. Treatment of cells with 4 μM of the
p38a inhibitor, 069A, led to a significant reduction in the levels of
IL-1b (C) and TNFa (D) in response to each of the different TLR
ligands. The white bar represents the BV-2 cells stimulated with the
ligand but without 069A (normalized to 100%). The black bar
represents the BV-2 cells treated with TLR ligand + 069A. Asterisk
denotes significance (* = p < 0.05, ** = p < 0.01, or *** = p <
0.001) for ligand-stimulated without 069A (white bar) compared to
stimulated with 069A (black bar). Data represent two independent
experiments.
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Figure 4 The p38a MAPK pathway is engaged in primary
microglia and contributes to cytokine upregulation. Rat primary
microglia were treated with either diluent (gray bars), stressor (either
1ng/ml LPS or 5 μM oligomeric Ab1-42) in the absence of 069A
(white bars), or stressor in the presence of 15 μM 069A (black bars).
The LPS-induced increases in IL-1b (A) and TNFa (B) levels by rat
primary microglia were significantly inhibited by the p38a inhibitor
069A. Similar results were obtained with a non-TLR ligand, Ab1-42.
LPS or Ab also caused an increase in the phosphorylated (active)
form of two p38a substrates, p-MK2 (C) and p-MSK1 (D), and
phosphorylation of these substrates was blocked by the addition of
069A. Asterisk denotes significance (* = p < 0.05, ** = p < 0.01, or
*** = p < 0.001) for stressor-stimulated microglia in the absence of
069A compared to stimulated microglia in the presence of 069A.
Values with stimulus alone (white bars) were normalized to 100%.
Data represent four independent experiments.

California USA, http://www.graphpad.com). Calculations
of IC50 values were made using a nonlinear regression
with a variable Hill slope, with the data normalized to the
positive control to fit the top and bottom plateaus.
Unless otherwise indicated, values are expressed as mean
± SEM. Groups of 2 were compared by unpaired T-test.
Groups of 3 or more were compared by One-way analysis
of variance (ANOVA), followed by Bonferroni Multiple
Comparison Test. Significance was defined as a p < 0.05.

Results
The p38a MAPK inhibitor, 069A, suppresses LPS-induced
cytokine up-regulation in the BV-2 microglial cell line

The ability of the small molecule p38a MAPK inhibitor,
compound 069A, to inhibit proinflammatory cytokine

up-regulation was tested in the mouse microglial BV-2
cell line. BV-2 cells were treated for 18 hrs with a standard activating stimulus, LPS (100 ng/ml), in the
absence or presence of increasing concentrations of
069A (0.9 μM to 30 μM), and then levels of IL-1b and
TNFa were measured. The results of four independent
experiments are shown in Figure 1A, B. Compound
069A produced a concentration-dependent inhibition of
both IL-1b (Figure 1A) and TNFa (Figure 1B) levels in
LPS-treated cells, reaching greater than 80% inhibition
at the 30 μM concentration. The calculated IC 50 for
suppression of IL-1b was 3.7 μM, with a 95% confidence
interval of 3.1 to 4.4 μM. The calculated IC50 for suppression of TNFa was 4.5 μM, with a 95% confidence
interval of 3.8 to 5.3 μM.
To provide insight into the temporal action of 069A,
we asked whether the compound would be effective
when given after stimulation or whether 069A needs to
be added to cells before or at the same time as stimulus.
We stimulated BV-2 cells with LPS (100 ng/ml), then
added 069A (at the IC 50 concentration of 4 μM) at
30min intervals up to 2 hrs after LPS treatment. IL-1b
and TNFa levels were then measured at 18 hrs after
LPS addition. As expected, 4 μM of 069A given at the
same time as LPS (time 0) resulted in approximately
50% inhibition of IL-1b (Figure 1C) and TNFa (Figure
1D). Interestingly, there was no loss in effectiveness
when 069A was given even 2 hrs after the LPS stimulation. This was confirmed in two independent
experiments.
LPS-induced phosphorylation of p38 substrates, MK2 and
MSK1, is reduced selectively by treatment with 069A

To confirm that 069A was inhibiting the p38a MAPK
pathway and to examine the selectivity of the downstream signaling responses, BV-2 cells were analyzed by
western blot for the levels of activated (phosphorylated)
p38 target proteins. Figure 2 shows results of five independent experiments. As expected, cells treated with
100 ng/ml LPS for one hr showed a significant increase
(p < 0.05) in the levels of the phosphorylated (activated)
forms of the four p38 substrates we examined: mitogenactivated protein kinase-activated protein kinase 2
(MK2), mitogen- and stress-activated kinase 1 (MSK1),
cyclic AMP response element binding protein (CREB),
and activating transcription factor-2 (ATF-2). We
explored the ability of 069A to suppress the LPSinduced phosphorylation of the p38 substrates. As
shown in Figure 2A, there was strong concentrationdependent inhibition (IC50 of 2.8 μM) of phosphorylated
(p)-MK2, a kinase whose activity is dependent on activation by p38a [28]. MSK1 is a kinase that can be phosphorylated by both p38 and Erk1/2 [29]. At a
concentration of 1.9 μM and higher, 069A significantly
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reduced the amount of p-MSK1, with an IC50 of 6.1 μM
(Figure 2B). CREB, which is a downstream target of
MSK1, was also significantly inhibited by 069A, but only
at a compound concentration of 15 μM or higher (Figure 2C). ATF2 is a target of JNK [30] as well as p38a/b
[31,32], and 069A did not inhibit p-ATF2 levels (Figure
2D). These data demonstrate that 069A shows selectivity
in its engagement of downstream substrates in the p38
MAPK pathway.
p38a MAPK is important for the cytokine response to
different TLR ligands

To confirm that the effects of 069A were not limited to
LPS stimulation, we tested the ability of 069A to suppress production of cytokines in BV-2 cells treated with
a panel of TLR ligands. We chose to examine ligands
for TLR2, TLR3, TLR4, TLR7/8, and TLR9 based on
three criteria. First, the expression of these receptors has
been shown to be elevated in areas of the brain associated with CNS neurodegenerative disease pathology
[33]. Second, microglia have been shown to express
these receptors [34]. Finally, ligands for these TLRs
induced a reproducible cytokine response in BV-2 cells.
As shown in Figure 3A, the TLR ligand panel produced
a significant increase in IL-1b, with the exception of the
TLR3 ligand poly(I:C). High molecular weight and low
molecular weight versions of poly(I:C) were tested, but
neither version resulted in a significant increase in IL1b. All the TLR ligands tested, including the TLR3
ligand poly(I:C), produced a large and significant (p <
0.0001) TNFa cytokine response (Figure 3B). Both versions of poly(I:C) produced similar increases in TNFa;
only data from the high molecular weight version of
poly(I:C) is shown.
We tested whether 069A would be effective at blocking
the increase in cytokines induced by TLR ligands. As
shown in Figure 3C, 4 μM 069A significantly (p < 0.001)
decreased the amount of IL-1b that was produced by the
BV-2 cells in response to each TLR ligand tested. The
percent inhibition by 069A with TLR2, TLR7/8, and
TLR9 ligands was not significantly different from the
inhibition seen with LPS, the TLR4 ligand. Similar results
were seen with TNFa production, where 069A treatment
resulted in a significant inhibition (p < 0.001) of TNFa
levels in response to all the TLR ligands (Figure 3D).
The p38a MAPK pathway is engaged in primary microglia
and contributes to cytokine up-regulation

To examine the generality of the response of stressorstimulated microglia to the p38a inhibitor 069A and
confirm that the results were not specific to the BV-2
cell line, we tested primary microglia stimulated with
either a TLR ligand (LPS) or a non-TLR ligand (Ab1-42).
The LPS-induced increases in IL-1b (Figure 4A) and

Page 7 of 12

TNFa (Figure 4B) levels in rat primary microglia were
significantly (p < 0.001) inhibited by 069A (15 μM).
Similar results were obtained with Ab1-42 (Figure 4A, B),
demonstrating that the p38a pathway is not limited to
TLR ligand activations. We also found that phosphorylation of the p38a MAPK substrates MK2 (Figure 4C) and
MSK1 (Figure 4D) was increased with ligand activation
of primary microglia, and that 069A treatment significantly decreased the levels of p-MK2 and p-MSK1.
To complement the pharmacological experiments and
confirm the importance of p38a, primary microglia
were isolated from p38a conditional knockout mice,
where p38a is genetically deficient in macrophages/
microglia. Control cells were microglia isolated from the
wild-type littermates. Upon stimulation of the microglia
cultures with 1ng/ml of LPS, we found an approximately
50% reduction in the levels of IL-1b (Figure 5A) and
TNFa (Figure 5B) in the p38a-deficient microglia compared to the wild-type microglia. Using a p38a-selective
antibody, we confirmed by Western blots that essentially
no p38a was detected in the knockout microglia (Figure
5C). There also was no compensatory increase in p38b
in these microglia, as antibodies that react with both
p38a and p38b showed little or no detectable reactivity
with the knockout microglia (Figure 5C). Finally, there
were substantially reduced levels of p-MSK1 or p-MK2
in the LPS-treated knockout microglia, confirming that
there is little to no activation of the p38a pathway in
these microglia. Altogether, these pharmacological and
genetic data demonstrate that the p38a MAPK pathway
is activated in ligand-stimulated primary microglia, and
that this pathway contributes to the microglial cytokine
up-regulation in response to diverse stressors.
Oral administration of 069A suppresses cytokine upregulation in vivo in response to LPS

LPS was used to produce an acute inflammatory
response in the brain to determine if 069A given orally
could reduce the CNS inflammatory response. In our
mouse model, we have found that an intraperitoneal (ip)
injection of LPS induces IL-1b up-regulation that peaks
at 6 hrs after the LPS stimulation (data not shown).
Therefore, 069A (5 mg/kg) was administered by oral
gavage 1 hr before LPS stimulation, mouse brain was
harvested at 6 hrs after LPS addition, and IL-1b levels in
the cortex were measured. As shown in Figure 6A, 069A
treatment caused a significant (p < 0.05) reduction in
the amount of IL-1b produced in the cortex following
LPS stimulation compared to the LPS-stimulated mice
that received vehicle. IL-1b was not detectable in the
non-LPS treated mice (data not shown). TNFa levels in
the LPS-treated mice were near basal levels at this time
point, so the ability of 069A to inhibit TNFa in cortex
could not be determined.
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Figure 5 Microglia deficient in p38a MAPK show a reduced cytokine response to LPS. Primary microglia isolated from either p38a
conditional KO mice (p38a-/-; black bar) or wild-type littermates (p38a+/+; white bar) were stimulated with 1ng/ml LPS for either 18 hrs (for
cytokine measurements) or 1 hr (for western blots). There was a significant reduction in the IL-1b (A) and TNFa (B) response to LPS in microglia
from the p38a KO mice compared to wild-type microglia. (C) There was also substantially reduced LPS-induced phosphorylation of p38a
substrates MSK1 and MK2 in p38a-/- microglia compared to p38a+/+ microglia. The loss of p38a in the KO microglia was confirmed by little or
no reactivity with a phospho-p38a/b antibody, a p38a/b antibody and a p38a-selective antibody. Asterisk denotes significance (*** = p < 0.001)
for p38a+/+ microglia (white bar) compared to p38a-/- microglia (black bar). Responses of the wild-type microglia were normalized to 100%.
Data represent three independent experiments.

In this acute LPS model, the effect of 069A could be
to inhibit the production of IL-1b from microglia, as
demonstrated in the cell culture studies. However, 069A
could also be lessening the initial response in the periphery to LPS and thereby reducing the severity of the
response in the CNS. To begin to address this possibility, we tested the potential of 069A to block the serum
cytokine response to LPS using a 90 min time point
that we have previously found to be the time of peak
response of serum TNFa to an ip LPS challenge. As
shown in Figure 6B, 069A did significantly reduce the
serum TNFa levels in mice administered LPS for 90
min (p < 0.05). The serum IL-1b levels were low and
there was no inhibition by 069A at this time point.

Discussion
We report here several findings with important implications for the treatment of CNS inflammation. First, we
show using both pharmacological and genetic
approaches that the p38a MAPK isoform is sufficient
for blocking a substantial portion of the IL-1b and
TNFa produced by microglia following LPS stimulation.
Second, using primary microglia and a microglia cell
line we show that the brain-penetrant p38a inhibitor,
069A, is able to block the cytokine response to diverse,
disease-relevant stimuli. Third, we demonstrate in vivo
that a single oral dose of 069A can block the IL-1b
response in the brain to a peripheral LPS insult. Fourth,
we show that 069A inhibits the activation of known
downstream targets of p38a, namely MK2 and MSK1,
and demonstrates selectivity in the signal transduction

pathways that it affects. Altogether, our data support the
idea that the p38a MAPK pathway is quantitatively
important for microglia proinflammatory cytokine upregulation in response to a variety of stressors, and that
the kinase may be a viable drug discovery target for
CNS disorders where overproduction of proinflammatory cytokines has been implicated in disease
progression.
Cytokines are inflammatory mediators that act throughout the body, including the CNS, via specific receptors
and signal transduction pathways. Clinical studies and preclinical animal models have provided extensive evidence to
support the hypothesis that overproduction of proinflammatory cytokines contributes to the progression of chronic
neurodegenerative disorders (for review, see [11]), as well
as to increased susceptibility to later-in-life disease or secondary injuries [35]. Microglia are the primary cell type in
the CNS responsible for the production of cytokines. We
were able to inhibit the production of two key proinflammatory cytokines, IL-1b and TNFa, with the p38a MAPK
inhibitor 069A at concentrations consistent with its ability
to block p38a kinase activity. Interestingly, we found that
069A was equally effective at blocking the production of
cytokines when the compound was given up to two hrs
after the LPS treatment; however, the mechanism underlying this observation was not pursued as part of this study.
The observation that 069A also suppresses the phosphorylation of two direct p38 substrates, MK2 and MSK1, provides additional evidence of target engagement in the
microglial cells. The inhibition of the active phosphorylated form of MK2 upon 069A treatment is consistent
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Figure 6 Oral administration of 069A suppresses LPS-induced
cortical IL-1b and serum TNFa in vivo: C57Bl/6 mice were
administered either saline vehicle or 069A (5mg/kg) by oral
gavage one hr prior to an intraperitoneal LPS (1mg/kg)
injection. Serum and cortex were harvested at 90 min and 6 hrs,
respectively, after LPS injection. (A) At the 6 hr timepoint, IL-1b
levels were significantly lower in the cortex of mice treated with
069A compared to vehicle-treated mice. TNFa levels in the cortex
were at or near the limit of detection of the assay. (B) At the 90
min timepoint, TNFa levels were significantly lower in the serum of
mice treated with 069A compared to vehicle-treated mice. Serum
IL-1b levels were low, and there was no inhibition by 069A at this
timepoint. Asterisk denotes significance (* = p < 0.05) for vehicletreated mice (white bar) compared to 069A-treated mice (black bar).
N = 5-8 per group.

with the observation [36] that MK2 kinase activity is
dependent on p38a MAPK for its phosphorylation and
activation. MK2 has also been reported to directly regulate
TNFa at the 3’-untranslated region (UTR) of mRNA in
the AU-rich elements [37], suggesting a potential mechanistic explanation for the action of 069A in suppression of
cytokine production. MSK1 can be phosphorylated and
activated by both p38a MAPK and ERK1/2 [29]. However,
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our observation that inhibition of p38a MAPK by 069A or
by genetic deletion leads to suppression of phosphorylated
MSK1 in the microglia cultures suggests that the p38a
MAPK pathway is playing a key role in transducing the
stressor stimulus to cytokine production in microglia.
In AD-relevant models, TLR2 and TLR4 have been
shown to be required for microglia cytokine response to
fibrillar Ab [38]. Microglia associated with senile plaques
exhibit elevated levels of TLR2/4/5/7/9 [33]. While the
role of TLRs in AD may be the best defined for any
CNS disorder to date, the potentially neurotoxic role of
TLRs is not limited to AD (for a recent review see:
[39,40]). The inflammatory cytokine response to TLR
ligands is typically through NF-B and MAPK signal
transduction pathways [41]. However, the response to
the ligands can vary depending on the cell type activated. In BV-2 cells we found that 069A was highly
effective at blocking the inflammatory cytokine response
to TLR2/3/4/7/8/9 ligands. This suggests that p38a
plays an important role in the signal transduction pathways that lead to inflammatory cytokines in microglia in
response to a variety of ligands, and that this kinase
may prove to be an effective convergence point that can
be targeted by small molecule inhibitors, such as 069A,
to block cytokine overproduction. Blocking p38a MAPK
in microglia, a principle source of inflammatory cytokines such as IL-1b, may ameliorate the detrimental
sequelae of increases in neuronal tau phosphorylation,
synaptic loss, or other cytokine-induced neuronal
damage responses [42-45]. In addition, inhibition of p38
MAPK in the neuron may also have beneficial consequences. Particularly relevant to AD, for example, are
reports showing that activation of neuronal p38 MAPK
contributes to Ab-induced impairment of cortical LTP
[46], and that p38 MAPK can phosphorylate tau in vitro
at sites seen in AD brain [47,48].
It should be emphasized that microglia responses to
stimuli can be neuroprotective and assist with phagocytosis or protein aggregate clearance, or can be detrimental and contribute to a progression of pathology
[13,49-51]. Therefore, attempts to develop disease-modifying therapeutics that target microglial activation
responses must be selective in their action (e.g., NOT
be pan-suppressors of glial activation such as steroids),
must consider the stage of disease progression and the
relative contribution of a given endpoint or signaling
pathway to the particular disease stage, and the appropriate dosing.
Dosing is the pharmacological foundation to selective
therapeutic intervention. Dosing includes the amount of
drug given normalized to body weight or volume and
includes the therapeutic time window for administration. The desired effect of a drug, therefore, requires a
combination of timing of administration based on
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mechanism of action and the amount administered. It is
a given that all drugs will have an adverse effect at some
dose, so safety with efficacy depends on finding the
appropriate concentration range over which the desired
effects are observed in the absence of undesired effects.
However, one can also obtain pharmacological selectivity with dosing, or one pharmacological effect at one
dose range and additional desired effects across a higher
dose range. Examples from prior art relative to modulating inflammation are instructive in this regard. Steroids
are used as anti-inflammatories, but are pleiotropic in
their actions. The pleiotropic effect contributes to a
diversity of pharmacological actions across efficacious
doses and to a comparatively narrow therapeutic range
in the absence of adverse events. In contrast, non-steroidal anti-inflammatories (NSAIDs) are more selective in
their action due to their targeting of the cyclooxygenases
and altering biologically active eicosanoids such as prostaglandins and thromboxanes. However, the NSAIDs
require appropriate dosing for safe and effective use due
to the fundamental importance of the widely distributed
cyclooxgenase targets in physiological processes (e.g.,
[52,53]). In the case of the NSAID drug aspirin, it can
be administered daily at a very low-dose for cardiovascular disease modification or ‘as needed’ dosing at
higher concentrations for CNS symptomatic effects (for
reviews, see [54,55]). It is anticipated that the pharmacodynamic (what the drug does to the body) effects of p38
MAPK inhibitors will be determined by the dosing regimen which must be empirically determined. The concentration-dependent target engagement in microglia
treated with a p38 MAPK inhibitor as shown in this
report is consistent with the achievement of a desired
pharmacodynamic effect through appropriate dosing.
However, the potential for dosing microglial product
endpoints studied here must be placed in the context of
other potential roles, such as effects on phagocytosis/
clearance or neuronal functions, which remain to be
dissected.
It is important to note that compound 069A is not a
NSAID as it does not target cyclooxgenases. In terms of
anti-inflammatory actions, 069A’s pharmacological
effects more closely resemble those of macromolecular
Biological Response Modifier drugs, such as the TNFa
blockers Etanercept or Infliximab, that alter inflammation-related pathology and exhibit extended pharmacodynamic effects after each administration. A goal of
p38a MAPK targeted drug development for CNS indications is to generate small molecule drugs that partially
mimic the biological actions of macromolecular biological response modifiers, yet are bioavailable, CNS-penetrant compounds that modulate disease-relevant
endpoints. The data presented here demonstrate that
pharmacological inhibition of p38a MAPK effectively
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suppresses the microglial cytokine upregulation response
to a number of different activating ligands, raising the
possibility for an extended pharmacodynamic effect due
to alteration of cytokine production.
In order to explore the potential for an in vivo effect
of 069A on cytokine levels, we screened for an effect on
the proinflammatory cytokine surge induced by LPS
administered ip. The results reveal a clear pharmacodynamic effect on brain cytokine level. Further exploration
of the mechanisms for this in vivo effect was not done
as part of this study, but deserves a cautionary comment. LPS administered ip will elicit a strong peripheral
inflammatory response, which is then transduced to the
brain via many pathways (for a recent review see: [56]).
Therefore, in the LPS model, one cannot distinguish
between a direct effect of a compound on microglia
cytokine induction or a more indirect effect that
involves reduction of the inflammatory response in the
periphery which then leads to a reduction in the CNS
response (or a combination of the two mechanisms).
Regardless, we previously reported [18] that oral administration of 069A attenuated excessive proinflammatory
cytokine production in the brain of an AD-relevant
mouse model stimulated centrally with a disease-relevant stressor (oligomeric Ab 1-42 ). Therefore, viewing
both our current and previous in vivo results in the context of the glial biology results indicates a probable
direct effect on microglia as one component of the therapeutic outcome. In addition, our results provide evidence that oral administration of 069A can reduce the
levels of IL-1b in the brain brought about by more than
one class of in vivo stressor.

Conclusions
Our results document a role for p38a MAPK as a critical
regulator of IL-1b and TNFa overproduction by microglia in response to TLR ligands, and indicate that p38a
MAPK also plays this key role in response to other
classes of microglial activators, including Ab1-42. In the
context of a rapidly growing literature in CNS drug discovery, the findings presented here suggest that therapeutic strategies targeting p38a MAPK pathways can be
potentially complementary to other disease progression
approaches to complex diseases and susceptibility to
injury where perturbation of glial-neuronal homeostasis
is involved in the mechanism of pathophysiology.
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